Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: Comparison of sparteine and dextromethorphan

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 5, 1996, Pages 583-592

  Kévorkian, Jean Philippe ^b   Michel, Catherine ^b   Hofmann, Ute ^b   Jacqz Aigrain, Evelyne ^b   Kroemer, Heyo K ^b   Peraldi, Marie Noëlle ^b   Eichelbaum, Michel ^b   Jaillon, Patrice ^b   Funck Brentano, Christian ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; DEXTROMETHORPHAN; SPARTEINE;

ADULT; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EXCRETION; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PHENOTYPE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; ANTITUSSIVE AGENTS; CREATININE; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OXYTOCICS; PHENOTYPE; REGRESSION ANALYSIS; SPARTEINE;

EID: 0029978651     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90187-3     Document Type: Article

References (29)

1. Brøsen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989;36:537-47.
2. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. Pharmacol Ther 1990;46:377-94.
3. Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 1984;25: 1057-64.
4. Shah RR, Oates NS, Idle JR, Smith RL, Lockhart JDF. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J 1982;284:295-9.
5. Oates NS, Shah RR, Idle JR, Smith RL. Phenformin-induced lacticacidosis associated with impaired debrisoquine hydroxylation. Lancet 1981;1:837-8.
6. Siddoway LA, Thompson KA, McAllister CB, et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987;75:785-91.
7. Lee JT, Kroemer HK, Silberstein DJ, et al. The role of genetically determined polymorphic drug metabolism in the betablockade produced by propafenone. N Engl J Med 1990;322:1764-8.
8. Funck-Brentano C, Turgeon J, Woosley RL, Roden DM. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics: influence of genetic polymorphism. J Pharmacol Exp Ther 1989;249: 134-42.
9. Sindrup SH, Brøsen K, Bjerring P, et al. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther 1991;49:686-93.
10. Broly F, Gaedig A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991;10:545-8.
11. Dayer P, Kronbach T, Eichelbaum M, Meyer UA. Enzymatic basis of the debrisoquine/sparteine type genetic polymorphism of drug oxidation. Characterization of bufuralol 1′-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency. Biochem Pharmacol 1987;36:4145-52.
12. Funck-Brentano C, Thomas G, Jacqz-Aigrain E, et al. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans. J Pharmacol Exp Ther 1992;263:780-6.
13. Schellens JHM, van der Wart JHF, Brugman M, Breimer DD. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design. J Pharmacol Exp Ther 1989;249:638-45.
14. Farrell GC. Drug metabolism in extrahepatic diseases. Pharmacol Ther 1987;35:375-404.
15. Touchette MA, Slaughter RL. The effect of renal failure on hepatic drug clearance. Drug Intell Clin Pharm 1991;25:1214-24.
16. Robertshaw M, Lai KN, Swaminathan R. Prediction of creatinine clearance from plasma creatinine: comparison of five formulae. Br J Clin Pharmacol 1989; 28:275-80.
17. Jacqz-Aigrain E, Médard Y, Popon M, Mathieu H. Dextromethorphan phenotypes determined by high-performance liquid chromatography and fluorescence detection. J Chromatogr 1989;495:361-3.
18. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989;43:53-76.
19. Eichelbaum M, Mineshita S, Ohnhaus EE, Zekorn C. The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol 1986;22:49-53.
20. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979; 16:183-7.
21. Walle T, Walle UK, Olanoff LS, Conradi EC. Partial metabolic clearances as determinants of the oral bioavailability of propranolol. Br J Clin Pharmacol 1986; 22:317-23.
22. Eichelbaum M, Woolhouse NM. Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans. Eur J Clin Pharmacol 1985;28:79-83.
23. Kupfer A, Schmid B, Pfaff G. Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica 1986;16:421-33.
24. Vetticaden SJ, Cabana BE, Prasad VK, et al. Phenotypic differences in dextromethorphan metabolism. Pharm Res 1989;6:13-9.
25. Fromm MF, Botsch S, Heinkele G, Evers J, Kroemer HK. Influence of renal function on the steady state pharmacokinetics of the antiarrhythmic propafenone and its phase I and II metabolites. Eur J Clin Pharmacol 1995;48:279-83.
26. Hou Z, Pickle LW, Meyer PS, Woosley RL. Salivary analysis for determination of dextromethorphan metabolic phenotype. Clin Pharmacol Ther 1991;49: 410-9.
27. Miners JO, Birkett DJ. The misuse of urinary metabolite excretion data in drug metabolism studies. Pharmacogenetics 1993;3:58-9.
28. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 1993;3: 197-204.
29. Kinirons MT, O'Shea D, Downing TE, et al. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 1993;54:621-9.